Research
The research activities of the Section of Hematology include both clinical and laboratory research. Details of research interests of each faculty are noted in their individual pages.
Current areas of laboratory research programs include immunobiology of plasma cell diseases, and cellular and molecular biology of blood cell production and hematopoiesis. The research activities are funded by the National Institutes of Health.
Areas of clinical research interest include myeloma and related plasma cell disorders, coagulopathies and non-malignant hematology , sickle cell disease, and palliative care .Other faculty affiliated with the section also carry out basic and clinical research related to hematology. Research programs in hematologic malignancies are in close collaboration with colleagues in the Hematology Program at Yale Cancer Center.
In addition to the individual research programs of primary faculty members of the Section of Hematology, collaborative research projects are ongoing with faculty members of several other departments, such as Laboratory Medicine, Pathology, Immunobiology and Genetics, who have common research interests
Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 2,514 publications
2024
- Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug DiscoveryChan A, Han L, Delaney C, Wang X, Mukhaleva E, Li M, Yang L, Pokharel S, Mattson N, Garcia M, Wang B, Xu X, Zhang L, Singh P, Elsayed Z, Chen R, Kuang B, Wang J, Yuan Y, Chen B, Chan L, Rosen S, Horne D, Müschen M, Chen J, Vaidehi N, Armstrong S, Su R, Chen C. Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Science Advances 2024, 10: eadk3127. PMID: 38394203, PMCID: PMC10889360, DOI: 10.1126/sciadv.adk3127.
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Badar T, Nanaa A, Atallah E, Shallis R, Guilherme S, Goldberg A, Saliba A, Patel A, Bewersdorf J, DuVall A, Bradshaw D, Abaza Y, Murthy G, Palmisiano N, Zeidan A, Kota V, Litzow M. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer Journal 2024, 14: 32. PMID: 38378617, PMCID: PMC10879201, DOI: 10.1038/s41408-024-01000-2.
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos Perez J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024, 1-7. PMID: 38378841, DOI: 10.1038/s41375-024-02175-0.
- Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centersAbaza Y, Winer E, Murthy S, Shallis R, Matthews A, Badar T, Geramita E, Kota V, Swaroop A, Doukas P, Bradshaw D, Helenowski I, Liu Y, Zhang H, Im A, Litzow M, Perl A, Atallah E, Altman J. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. American Journal Of Hematology 2024 PMID: 38342997, DOI: 10.1002/ajh.27231.
- Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory SettingGarg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.
- Current Opinion in HematologyHalene S. Current Opinion in Hematology. Current Opinion In Hematology 2024, 31: 39. DOI: 10.1097/moh.0000000000000799.
- 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AMLNath R, Seropian S, Gyurkocza B, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Tomlinson B. 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML. Transplantation And Cellular Therapy 2024, 30: s54-s55. DOI: 10.1016/j.jtct.2023.12.089.
- 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved OutcomesForan J, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Nagl N, Brodin P, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Seropian S. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes. Transplantation And Cellular Therapy 2024, 30: s110-s111. DOI: 10.1016/j.jtct.2023.12.174.
- Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AMLChen G, Abboud C, Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Leung E, Chen M, Natwa M, Spross J, Li K, Desai A, Wahl R, Brodin P, Pandit-Taskar N. Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML. Transplantation And Cellular Therapy 2024, 30: s114-s115. DOI: 10.1016/j.jtct.2023.12.180.
- Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust EngraftmentChoe H, Nath R, Seropian S, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Gyurkocza B. Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment. Transplantation And Cellular Therapy 2024, 30: s59-s60. DOI: 10.1016/j.jtct.2023.12.094.
- Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene VicleucelAkhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.
- Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.
- Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resourceIto S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024 PMID: 38279581, DOI: 10.1002/ajh.27211.
- Racial differences in treatment and survival among older patients with multiple myelomaWang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.
- Perspectives of Adolescents and Young Adults With Sickle Cell Disease and Clinicians on Improving Transition Readiness With a Video Game InterventionAronson P, Nolan S, Schaeffer P, Hieftje K, Ponce K, Calhoun C. Perspectives of Adolescents and Young Adults With Sickle Cell Disease and Clinicians on Improving Transition Readiness With a Video Game Intervention. Journal Of Pediatric Hematology/Oncology 2024, 46: e147-e155. PMID: 38237001, DOI: 10.1097/mph.0000000000002810.
- Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort studyThanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.
- Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemiaHuntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.
2023
- Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaGerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsBewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, Irish J, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals Of Hematology 2023, 103: 105-116. PMID: 38036712, DOI: 10.1007/s00277-023-05552-4.
- Abstract B115: Racial and ethnic disparities in the incidence and mortality trends of acute myeloid leukemia in the United StatesKang L, Ma X, Podoltsev N, Stempel J, Wang R. Abstract B115: Racial and ethnic disparities in the incidence and mortality trends of acute myeloid leukemia in the United States. Cancer Epidemiology Biomarkers & Prevention 2023, 32: b115-b115. DOI: 10.1158/1538-7755.disp23-b115.
- Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple MyelomaBrowning S, Li A, Parker T, Bar N, Anderson T, Stevens E, Liu Y, Matthews M, VanOudenhove J, Cardone R, Sun Q, Hale R, Halene S, Kibbey R, Neparidze N. Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood 2023, 142: 4774. DOI: 10.1182/blood-2023-186401.
- Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) RegistryPine A, Butt A, Garcia-Milian R, Gu S, Restrepo V, Chock Y, Hwa J, Tormey C, Rinder H, Goshua G, Belmont H, Bertolaccini M, Branch D, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee A, Sharda A. Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Blood 2023, 142: 2575. DOI: 10.1182/blood-2023-185232.
- Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 TrialShallis R, Blaha O, Halene S, Mendez L, Podoltsev N, Caldwell A, Bewersdorf J, Little R, Piekarz R, Patnaik M, Gore S, Zeidan A. Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial. Blood 2023, 142: 3252. DOI: 10.1182/blood-2023-182814.
- Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction TherapyHunter C, Cheng W, Halene S, Mendez L, Podoltsev N, Zeidan A, Barbarotta L, Shallis R. Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy. Blood 2023, 142: 589. DOI: 10.1182/blood-2023-182989.
- Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center ExperienceHamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.
- Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United StatesStempel J, Li A, Pine A, Restrepo V, Bewersdorf J, Stahl M, Podoltsev N, Mendez L, Shallis R, Rangachari D, Lee A, Michaelis L, Zeidan A. Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States. Blood 2023, 142: 2319. DOI: 10.1182/blood-2023-187163.
- The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic DisordersWorst M, Friedman H, Bomba S, Whitney M, Middleton D, Mikhael E, Kadkhoda H, Zhang C, Podoltsev N. The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic Disorders. Blood 2023, 142: 7282. DOI: 10.1182/blood-2023-180360.
- State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United StatesKang L, Ma X, Podoltsev N, Stempel J, Wang R. State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United States. Blood 2023, 142: 5184. DOI: 10.1182/blood-2023-186428.
- A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)Maher K, Rampal R, Bose P, Podoltsev N, Harrison C, Hong J, Wang X, Chamoun K, Mascarenhas J. A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034). Blood 2023, 142: 3209. DOI: 10.1182/blood-2023-180695.
- Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) StudyAjufo H, Derkach A, Rampal R, Famulare C, Nemirovsky D, Chervin J, Ho V, Gupta V, Viswabandya A, Deeg H, Monahan T, Jain T, Jones R, Palmer J, Gerds A, Keyzner A, Lagdameo J, Gomez-Arteaga A, Van Besien K, Podoltsev N, Puzo C, Kosuri S, Amanam I, Tamari R. Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study. Blood 2023, 142: 3181. DOI: 10.1182/blood-2023-173441.
- A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGarcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland S, Litzow M, Savoie M, Medeiros B, Sekeres M, Lin T, Uy G, Powell B, Kolitz J, Larson R, Stone R, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba H. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 2023, 38: 58-66. PMID: 37935977, DOI: 10.1038/s41375-023-02073-x.
- Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant.VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle NT, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant. BioRxiv 2023 PMID: 37961434, DOI: 10.1101/2023.10.26.564259.
- High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyZayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
- Peripheral Blasts in a Patient Receiving ChemotherapyKshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.
- Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaHuntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.
- Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
- Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progressionEcker V, Brandmeier L, Stumpf M, Giansanti P, Moreira A, Pfeuffer L, Fens M, Lu J, Kuster B, Engleitner T, Heidegger S, Rad R, Ringshausen I, Zenz T, Wendtner C, Müschen M, Jellusova J, Ruland J, Buchner M. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Reports 2023, 42: 113017. PMID: 37792532, DOI: 10.1016/j.celrep.2023.113017.
- PULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATIONSTEMPEL J, BAR N. PULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION. CHEST Journal 2023, 164: a1049-a1050. DOI: 10.1016/j.chest.2023.07.768.
- ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability controlGao Y, Zimmer J, Vasic R, Liu C, Gbyli R, Zheng S, Patel A, Liu W, Qi Z, Li Y, Nelakanti R, Song Y, Biancon G, Xiao A, Slavoff S, Kibbey R, Flavell R, Simon M, Tebaldi T, Li H, Halene S. ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell Reports 2023, 42: 113163. PMID: 37742191, PMCID: PMC10636609, DOI: 10.1016/j.celrep.2023.113163.
- Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.
- Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.Park J, Devlin S, Durham B, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Falco V, Cuello B, Gore S, Stone R, Abdel-Wahab O, Tallman M. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM Evidence 2023, 2: evidoa2300074. PMID: 38320179, DOI: 10.1056/evidoa2300074.
- PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphomaWartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani A, Cernilogar F, van Heijster F, Hundshammer C, Schneider H, Konstantinidis F, Gabler J, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock D, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nature Cancer 2023, 4: 1508-1525. PMID: 37723306, PMCID: PMC10597841, DOI: 10.1038/s43018-023-00635-7.
- Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaPodoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.
- P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical studyCosta L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.
- Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.
- Integrative analysis of transcriptome dynamics during human craniofacial development identifies candidate disease genesYankee T, Oh S, Winchester E, Wilderman A, Robinson K, Gordon T, Rosenfeld J, VanOudenhove J, Scott D, Leslie E, Cotney J. Integrative analysis of transcriptome dynamics during human craniofacial development identifies candidate disease genes. Nature Communications 2023, 14: 4623. PMID: 37532691, PMCID: PMC10397224, DOI: 10.1038/s41467-023-40363-1.
- P745: MULTI‐CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTSBewersdorf J, Shallis R, Sharon E, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Pierkarz R, Gore S, Kim T, Zeidan A. P745: MULTI‐CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS. HemaSphere 2023, 7: e30347e2. PMCID: PMC10428733, DOI: 10.1097/01.hs9.0000969884.30347.e2.
- P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCELRasheed Y, Mirza A, Pine A, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL. HemaSphere 2023, 7: e19857ae. PMCID: PMC10430478, DOI: 10.1097/01.hs9.0000972428.19857.ae.
- P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRYButt A, Garcia-Milian R, Goshua G, Gu S, Hwa J, Chun H, Belmont H, Kello N, Branch D, Petri M, Knight J, Willis R, Bertolaccini M, Erkan D, Lee A, Sharda A, Pine A. P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRY. HemaSphere 2023, 7: e160607f. PMCID: PMC10429839, DOI: 10.1097/01.hs9.0000973420.16060.7f.
- P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCELMirza A, Pine A, Hamouche R, Rasheed Y, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL. HemaSphere 2023, 7: e1847498. PMCID: PMC10430598, DOI: 10.1097/01.hs9.0000972412.18474.98.
- P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTINGGarg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Chakraborty S, Doshi J, Huntington S. P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING. HemaSphere 2023, 7: e7912542. PMCID: PMC10429930, DOI: 10.1097/01.hs9.0000973652.79125.42.
- P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDYWong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.
- Influence of participant and reviewer characteristics in application scores for a hematology research training programVesely S, King A, Vettese E, Heller J, Cuker A, Calhoun C, Stock W, Homer M, Fritz J, Sung L. Influence of participant and reviewer characteristics in application scores for a hematology research training program. Blood Advances 2023, 7: 4064-4071. PMID: 36939221, PMCID: PMC10388723, DOI: 10.1182/bloodadvances.2023009792.
- Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costsSquires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 2023, 64: 1752-1770. PMID: 37497877, DOI: 10.1080/10428194.2023.2234525.
- Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)Butt A, Allen C, Purcell A, Ito S, Goshua G. Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP). Journal Of Clinical Medicine 2023, 12: 4887. PMID: 37568288, PMCID: PMC10420213, DOI: 10.3390/jcm12154887.
- The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cellsBrina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D’Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff J, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature Cancer 2023, 4: 1102-1121. PMID: 37460872, DOI: 10.1038/s43018-023-00594-z.
- Aiming for the cure in myeloma: Putting our best foot forwardBar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.
- Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United StatesPotnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.
- Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherenceShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider supportLee A, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O’Connell C, Rajasekhar A, Reynolds R, Sharma D, Smith M, Weeks LD, Erikson CE. Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances 2023, 7: 3058-3068. PMID: 35476017, PMCID: PMC10331414, DOI: 10.1182/bloodadvances.2021006140.
- Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLPratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J, Lin T, Schiller G, Jurcic J, Asch A, Wu R, Hill J, Gill S, James A, Rich E, Hasabou N, Perl A, Levis M. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal Of Clinical Oncology 2023, 41: 4236-4246. PMID: 37379495, DOI: 10.1200/jco.22.02721.
- A novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinomaChen Z, Ge L, Xu S, Li Q, Zhou L. A novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinoma. Scientific Reports 2023, 13: 9921. PMID: 37337018, PMCID: PMC10279685, DOI: 10.1038/s41598-023-36720-1.
- Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysisRagon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.
- An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSStahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.
- FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical OutcomesAvery J, Kim R, Cheng W, Foss F, Girardi M. FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes. JID Innovations 2023, 3: 100212. PMID: 37674691, PMCID: PMC10477749, DOI: 10.1016/j.xjidi.2023.100212.
- Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine ProtectionKim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialPlatzbecker U, Della Porta M, Santini V, Zeidan A, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Shetty J, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. The Lancet 2023, 402: 373-385. PMID: 37311468, DOI: 10.1016/s0140-6736(23)00874-7.
- Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation.Broso F, Gatto P, Sidarovich V, Ambrosini C, De Sanctis V, Bertorelli R, Zaccheroni E, Ricci B, Destefanis E, Longhi S, Sebastiani E, Tebaldi T, Adami V, Quattrone A. Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation. Cancer Research 2023, 83: 2733-2749. PMID: 37289021, DOI: 10.1158/0008-5472.can-22-1913.
- Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphomaPotnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.
- Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.
- Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib. Journal Of Clinical Oncology 2023, 41: e19080-e19080. DOI: 10.1200/jco.2023.41.16_suppl.e19080.
- Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.Niyogusaba T, Switchenko J, Rozati S, Iyer S, Talluru S, Huen A, Greenwell I, Scribner J, Rangarajan S, Mehta A, Beaven A, Bhatti S, Krishanasamy S, Porcu P, Sethi T, Foss F, Paulino D, Case K, Lechowicz M, Allen P. Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis. Journal Of Clinical Oncology 2023, 41: 7573-7573. DOI: 10.1200/jco.2023.41.16_suppl.7573.
- The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.
- A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).Olszewski A, Huntington S, Ollila T, Pelcovits A, McMahon J, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2023, 41: tps7588-tps7588. DOI: 10.1200/jco.2023.41.16_suppl.tps7588.
- Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).Garcia-Manero G, Platzbecker U, Santini V, Zeidan A, Fenaux P, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Kreitz S, Pozharskaya V, Shetty J, Degulys A, Finelli C, Cluzeau T, Della Porta M. Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS). Journal Of Clinical Oncology 2023, 41: 7003-7003. DOI: 10.1200/jco.2023.41.16_suppl.7003.
- IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).Zeidan A, Platzbecker U, Santini V, Fenaux P, Sekeres M, Savona M, Madanat Y, Diez-Campelo M, Valcarcel D, Illmer T, Jonasova A, Belohlavkova P, Sherman L, Berry T, Dougherty S, Shah S, Sun L, Wan Y, Huang F, Komrokji R. IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA). Journal Of Clinical Oncology 2023, 41: 7004-7004. DOI: 10.1200/jco.2023.41.16_suppl.7004.
- Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).Zeidan A, Hernandez Donoso L, Hodzic S, Owusu H, Pathak D, Zhou S, Stein E. Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA). Journal Of Clinical Oncology 2023, 41: 7044-7044. DOI: 10.1200/jco.2023.41.16_suppl.7044.
- Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.Zeidan A, Fathi A, Issa G, Erba H, Ahsan J, Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. Journal Of Clinical Oncology 2023, 41: tps7079-tps7079. DOI: 10.1200/jco.2023.41.16_suppl.tps7079.
- Diversity, equity, and inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.Ansari N, Fanucci K, Burtness B, Goldberg S, Hurwitz M, Podoltsev N, Lee A, Kunz P. Diversity, equity, and inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum. Journal Of Clinical Oncology 2023, 41: 11002-11002. DOI: 10.1200/jco.2023.41.16_suppl.11002.
- A multifaceted approach to wellness in a hematology/oncology fellowship program.Srikumar T, Ansari N, Fanucci K, Goldberg S, Hurwitz M, Podoltsev N, Lee A, Sanft T. A multifaceted approach to wellness in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2023, 41: 11006-11006. DOI: 10.1200/jco.2023.41.16_suppl.11006.
- EE158 Healthcare Resource Utilization and Costs Among Medicare Beneficiaries Initiating Venetoclax Vs. Btkis for Relapsed/Refractory Chronic Lymphocytic Leukemia: A Real-World StudyHuntington S, Manzoor B, Jawaid D, Puckett J, Alhasani H, Ravelo A, Kamal-Bahl S, Emechebe N, Doshi J. EE158 Healthcare Resource Utilization and Costs Among Medicare Beneficiaries Initiating Venetoclax Vs. Btkis for Relapsed/Refractory Chronic Lymphocytic Leukemia: A Real-World Study. Value In Health 2023, 26: s88-s89. DOI: 10.1016/j.jval.2023.03.461.
- Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.
- Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesPatel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 674-686. PMID: 37290996, DOI: 10.1016/j.clml.2023.05.002.
- Visualizing gene expression changes in time, space, and single cells with expressyouRcellPaganin M, Tebaldi T, Lauria F, Viero G. Visualizing gene expression changes in time, space, and single cells with expressyouRcell. IScience 2023, 26: 106853. PMID: 37250782, PMCID: PMC10220493, DOI: 10.1016/j.isci.2023.106853.
- Supportive Care for Patients With Myelodysplastic SyndromesStempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.
- Examining Mental Health, Education, Employment, and Pain in Sickle Cell DiseaseHarris K, Preiss L, Varughese T, Bauer A, Calhoun C, Treadwell M, Masese R, Hankins J, Hussain F, Glassberg J, Melvin C, Gibson R, King A. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease. JAMA Network Open 2023, 6: e2314070. PMID: 37200033, PMCID: PMC10196879, DOI: 10.1001/jamanetworkopen.2023.14070.
- Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesPatel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia 2023 DOI: 10.1016/j.clml.2023.05.002.
- Epidemiology and Pathogenesis of Myelodysplastic SyndromeRotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. The Cancer Journal 2023, 29: 111-121. PMID: 37195766, DOI: 10.1097/ppo.0000000000000665.
- Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and TreatmentsRose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.
- Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
- Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/NeoplasmsStempel J, Xie Z, Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms. The Cancer Journal 2023, 29: 203-211. PMID: 37195777, DOI: 10.1097/ppo.0000000000000666.
- Novel Approaches and Future Directions in Myelodysplastic Syndrome TreatmentBewersdorf J, Xie Z, Zeidan A. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment. The Cancer Journal 2023, 29: 195-202. PMID: 37195776, DOI: 10.1097/ppo.0000000000000658.
- CD25 recruits inhibitory phosphatases for feedback control of B-cell receptor signalingSun R, Lee J, Robinson M, Kume K, Cosgun K, Chan L, Leveille E, Geng H, Vykunta V, Shy B, Marson A, Meffre E, Müschen M. CD25 recruits inhibitory phosphatases for feedback control of B-cell receptor signaling. The Journal Of Immunology 2023, 210: 154.23-154.23. DOI: 10.4049/jimmunol.210.supp.154.23.
- β-catenin engages IKZF factors to control lymphopoiesisCosgun K, Jumaa H, Robinson M, Xu L, Xiao G, Arce D, Khanduja D, Chan L, Lee J, Schjerven H, Jellusova J, Müschen M. β-catenin engages IKZF factors to control lymphopoiesis. The Journal Of Immunology 2023, 210: 65.09-65.09. DOI: 10.4049/jimmunol.210.supp.65.09.
- Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic SyndromeAllen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome. Acta Haematologica 2023, 146: 287-292. PMID: 37166332, DOI: 10.1159/000530153.
- Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 AxisLi M, Yang L, Chan A, Pokharel S, Liu Q, Mattson N, Xu X, Chang W, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan L, Lee J, Zhang X, Rosen S, Müschen M, Qi J, Chen J, Hiom K, Bishop A, Chen C. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis. Advanced Science 2023, 10: 2206584. PMID: 37075745, PMCID: PMC10265057, DOI: 10.1002/advs.202206584.
- TERRA stability is regulated by RALY and polyadenylation in a telomere-specific mannerSavoca V, Rivosecchi J, Gaiatto A, Rossi A, Mosca R, Gialdini I, Zubovic L, Tebaldi T, Macchi P, Cusanelli E. TERRA stability is regulated by RALY and polyadenylation in a telomere-specific manner. Cell Reports 2023, 42: 112406. PMID: 37060569, DOI: 10.1016/j.celrep.2023.112406.
- What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational ApproachAwada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.
- Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer Network 2023, 21: 522-528. PMID: 37037494, DOI: 10.6004/jnccn.2023.70012.
- Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA exportOlazabal-Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Teng Y, Lan L, Chen X, Pei H, Pillai M, Sung P, Kupfer G. Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA export. Cancer Research 2023, 83: 6100-6100. DOI: 10.1158/1538-7445.am2023-6100.